Marsh McLennan projects mid-single-digit revenue growth for 2025 amid strong Q4 performance (NYSE:MMC)January 30, 2025
Market Trends FDA accepts Teva, Alvotech BLAs for Simponi biosimilars (TEVA:NYSE)By admin8996erT0allJanuary 27, 2025 JHVEPhotoThe FDA has accepted Alvotech (NASDAQ:ALVO) and Teva’s (NYSE:TEVA) Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory…
